BenevolentAI Investor Conference Presentation Deck

Robust pipeline entirely generated by the Benevolent Platform™ BEN-2293 | Atopic Dermatitis BEN-8744 | Ulcerative Colitis BEN-28010 | Glioblastoma Multiforme BEN-9160 | Amyotrophic Lateral Sclerosis Inflammatory Bowel Disease Amyotrophic Lateral Sclerosis Antiviral Oncology Oncology Parkinson's Disease Nonalcoholic Steatohepatitis (NASH) Oncology Parkinson's Disease Fibrosis Inflammation Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Chronic Kidney Disease +10 Exploratory stage programmes Target ID Chemistry & Lead Opt AstraZeneca AstraZeneca Preclinical AstraZeneca 27.01.2021 15.12.2021 AstraZeneca 17.05.2022 06.10.2022 AstraZeneca 06.10.2022 Phase I Phase II Highlights Focus on complex multifactorial diseases • Broad therapy area coverage enabled by disease-agnostic Platform, with future investment to focus on three therapeutic indications • Balance of risk between "best in class" and "first in class" drug candidates • Potential for rapid scaling and expansion into new modalities Benevolent 24

View entire presentation